ArticleJournal of hematology & oncology2016
L-asparaginase-based regimens followed by allogeneic hematopoietic stem cell transplantation improve outcomes in aggressive natural killer cell leukemia.
Article in Journal of hematology & oncology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 41 citations in OpenAlex.
- [Aggressive NK-cell leukemia with CD5(+)CD10(-) monoclonal B cell lymphocytosis and hemophagocytic lymphohistiocytosis: a case report and literature review].Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi · 2026Review
- EBV-Driven NK/T-Cell Lymphoproliferative Disorders: Clinical Diversity and Molecular Insights.Lymphatics · 2026Article
- Advances in the treatment and prognosis of aggressive NK-cell leukemia: results from the ANKL22 study.Leukemia · 2026Article
- Aggressive natural killer cell leukemia therapy in the L-asparaginase era: why are we failing?Blood research · 2025Article
- Case report: a critically ill patient with aggressive NK-cell leukemia receiving emergency chemotherapy in the ICU.Virology journal · 2025Article
- Integration of anti-PD-1 antibody into chemotherapeutic regimens improved the outcome of aggressive NK cell leukemia: a single-center retrospective real-world analysis.Frontiers in immunology · 2025Article
- Case Report: Transformation of natural killer-cell large granular lymphocytic leukemia to aggressive natural killer cell leukemia.Frontiers in oncology · 2025Article
- Natural Killer Cell Activity Test Helps to Suspect Aggressive Natural Killer Cell Leukemia - Diagnostic Challenge.International journal of medical sciences · 2023Article
- [Clinical characteristics and prognosis of patients with aggressive NK cell leukemia].Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi · 2022Article
- Aggressive Natural Killer Cell Leukemia in an Adolescent Patient: A Case Report and Literature Review.Frontiers in pediatrics · 2022Article
- [Outcome of haploidentical hematopoietic stem cell transplantation for aggressive natural killer cell leukemia].Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi · 2021Article
- Allogeneic stem cell transplantation for patients with aggressive NK-cell leukemia.Bone marrow transplantation · 2021Article
- Chronic active Epstein-Barr virus infection progresses to aggressive NK cell leukemia with a poor prognosis.American journal of translational research · 2021Article
- Aggressive NK Cell Leukemia: Current State of the Art.Cancers · 2020Review
- Identification of a novel CCDC22 mutation in a patient with severe Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis and aggressive natural killer cell leukemia.International journal of hematology · 2019Article
- Clinical efficacy of cisplatin, dexamethasone, gemcitabine and pegaspargase (DDGP) in the initial treatment of advanced stage (stage III-IV) extranodal NK/T-cell lymphoma, and its correlation with Epstein-Barr virus.Cancer management and research · 2019Article
- Cyclin-dependent kinase 9 as a potential specific molecular target in NK-cell leukemia/lymphoma.Haematologica · 2018Article
- Aggressive natural killer cell leukemia mimicking interstitial lung diseases with the activation of the mitogen-activated protein kinase pathway.International journal of clinical and experimental pathology · 2018Article
- Aggressive NK-Cell Leukemia.Frontiers in pediatrics · 2018Review
- Aggressive NK-cell leukemia: clinical subtypes, molecular features, and treatment outcomes.Blood cancer journal · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Aggressive nature killer cell leukemia (ANKL) is a mature NK-T cell lymphoma with worse prognosis, but optimal treatment is unclear. Therefore, we analyzed the efficacy of L-asparaginase-based regimens for ANKL patients. Twenty-one patients who received dexamethasone, methotrexate, ifosfamide, L-asparaginase, and etoposide (SMILE) or etoposide, ifosfamide, dexamethasone, and L-asparaginase (VIDL) chemotherapy at Samsung Medical Center were selected. The overall response rate for all patients was 33% (7/21); 38% (5/13) in SMILE and 40% (2/5) in VIDL, respectively. The median progression-free survival was 3.9 months (95% CI 0.0-8.1 months) and median overall survival was 7.0 months (95% CI 2.3-11.7 months). Treatment response (P = 0.001), hematopoietic stem cell transplantation (HSCT) (P = 0.007) and negative conversion of Epstein-Barr virus (EBV) DNA titer after treatment (P = 0.004) were significantly associated with survival. Thus, L-asparaginase-based regimens followed by allogeneic HSCT seem to improve the outcome for ANKL patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.